

Laure Gossec

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/4563481/publications.pdf](https://exaly.com/author-pdf/4563481/publications.pdf)

Version: 2025-02-01

301

PR articles

19,759

PR citations

13055

59

PR h-index

7367

136

g-index

358

documents

22818

doc citations

13289

64

h-index

19507

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Évaluation globale standardisée systématique des rhumatismes inflammatoires chroniques: intérêts et limites. Revue Du Rhumatisme (Edition Francaise), 2025, 92, 16-25.	0.0	0
2	Subclinical psoriatic arthritis and disease interception—where are we in 2024?. Rheumatology, 2025, 64, 56-64.	2.0	15
3	Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial. Annals of the Rheumatic Diseases, 2025, 84, 49-59.	12.4	13
4	Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry. Arthritis Care and Research, 2024, 76, 274-287.	3.0	8
5	Ten-year clinical outcome of recent-onset axial spondyloarthritis: Results from the DESIR inception Cohort. Joint Bone Spine, 2024, 91, 105678.	2.3	16
6	Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis. RMD Open, 2024, 10, e003548.	4.2	4
7	Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis. Arthritis Research and Therapy, 2024, 26, .	4.2	6
8	Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?. RMD Open, 2024, 10, e003972.	4.2	3
9	Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open, 2024, 10, e003855.	4.2	26
10	Is the patient-perceived impact of psoriatic arthritis a global concept? An international study in 13 Arab countries (TACTIC study). Rheumatology International, 2024, 44, 885-899.	2.7	6
11	Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 2024, 83, 760-774.	12.4	54
12	Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial. Arthritis Care and Research, 2024, 76, 1139-1148.	3.0	2
13	Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD Open, 2024, 10, e003977.	4.2	10
14	Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative. Joint Bone Spine, 2024, 91, 105733.	2.3	0
15	Disease activity and widespread pain are main contributors to patient-reported global health in axial spondyloarthritis: an analysis of 6064 patients. Rheumatology International, 2024, 44, 1455-1468.	2.7	9
16	Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open, 2024, 10, e004314.	4.2	22
17	Patient research partner involvement in rheumatology research: a systematic literature review informing the 2023 updated EULAR recommendations for the involvement of patient research partners. Annals of the Rheumatic Diseases, 2024, 83, 1268-1277.	12.4	6
18	Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies. Rheumatology, 2024, 63, 2399-2410.	2.0	5

#	ARTICLE	IF	PR CITATIONS
19	Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry. <i>Annals of the Rheumatic Diseases</i> , 2024, 83, 1584-1595.	12.4	5
20	Unmet needs in psoriatic arthritis, a narrative review. <i>Archives of Rheumatology</i> , 2024, 39, 159-171.	0.8	7
21	Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. <i>RMD Open</i> , 2024, 10, e004484.	4.2	1
22	Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2024, 6, 720-731.	1.9	2
23	Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 <scp>SELECT</scp> PsA</scp> 1 and 2 Randomized Controlled Trials. <i>ACR Open Rheumatology</i> , 2024, 6, 736-745.	1.9	3
24	Barriers to, Facilitators of, and Interventions to Support Treatment Target Implementation in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2024, 76, 1626-1636.	3.0	5
25	Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2024, 83, 1480-1488.	12.4	7
26	Patients with axial spondyloarthritis reported willingness to use remote care and showed high adherence to electronic patient-reported outcome measures: an 18-month observational study. <i>Rheumatology International</i> , 2024, 44, 2089-2098.	2.7	5
27	Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2024, 11, 1363-1382.	2.2	10
28	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. <i>Rheumatology</i> , 2023, 62, 606-616.	2.0	13
29	Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. <i>Rheumatology</i> , 2023, 62, 617-628.	2.0	13
30	Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2023, 50, 56-65.	2.4	9
31	Women With Psoriatic Arthritis Experience Higher Disease Burden Than Men: Findings From a Real-World Survey in the United States and Europe. <i>Journal of Rheumatology</i> , 2023, 50, 192-196.	2.4	29
32	Impact of Physician-Defined Flares on Quality of Life and Work Impairment: An International Survey of 2238 Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2023, 50, 76-83.	2.4	3
33	Challenges in interpreting sacroiliac magnetic resonance imaging for the diagnosis of axial spondyloarthritis. <i>Joint Bone Spine</i> , 2023, 90, 105470.	2.3	3
34	Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance. <i>Arthritis Care and Research</i> , 2023, 75, 53-60.	3.0	17
35	Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 496-506.	12.4	18
36	Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. <i>Rheumatology</i> , 2023, 62, 3382-3390.	2.0	18

#	ARTICLE	IF	PR CITATIONS
37	Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 698-709.	12.4	16
38	Influence of Sex on Early Axial Spondyloarthritis: A Six-Year Longitudinal Analysis From a Large National Cohort. <i>Arthritis Care and Research</i> , 2023, 75, 2107-2116.	3.0	6
39	Work-Related Issues and a High Burden of Disease Are Frequent in Axial Spondyloarthritis: What Should We Be Doing Better?. <i>Journal of Rheumatology</i> , 2023, 50, 581-582.	2.4	2
40	Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study. <i>Arthritis Research and Therapy</i> , 2023, 25, .	4.2	3
41	Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. <i>RMD Open</i> , 2023, 9, e003143.	4.2	29
42	Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2023, 50, 53-57.	2.4	13
43	Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 1404-1414.	12.4	34
44	Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study. <i>RMD Open</i> , 2023, 9, e003157.	4.2	14
45	Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials. <i>Arthritis Care and Research</i> , 2022, 74, 759-767.	3.0	14
46	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis. <i>Rheumatology</i> , 2022, 61, 2054-2062.	2.0	5
47	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	2.4	9
48	Exploring remission concept in axial spondyloarthritis through the perception of rheumatologists using vignettes and priority ratings. <i>Rheumatology</i> , 2022, 61, 2603-2608.	2.0	4
49	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 359-369.	12.4	85
50	2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. <i>Joint Bone Spine</i> , 2022, 89, 105344.	2.3	97
51	Actualisation 2022 des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite, incluant le rhumatisme psoriasique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2022, 89, 210-222.	0.0	9
52	Correspondence on Examining remission definitions in rheumatoid arthritis: considering the Joint Disease Activity Score, C-reactive protein level and patient global assessment by Felson et al. <i>ACR Open Rheumatology</i> , 2022, 4, 271-272.	1.9	1
53	Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years. <i>RMD Open</i> , 2022, 8, e001986.	4.2	9
54	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	12.4	159

#	ARTICLE	IF	PR CITATIONS
55	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 823-830.	12.4	22
56	Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial. <i>RMD Open</i> , 2022, 8, e001828.	4.2	22
57	Development and validation of a self-administered questionnaire measuring essential knowledge in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2022, 42, 1785-1795.	2.7	9
58	Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. <i>Rheumatology</i> , 2022, 61, 3257-3268.	2.0	21
59	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	4.2	50
60	P260â€fSecukinumab in Patients With Psoriatic Arthritis and Axial Manifestations: Predictors of Response From the Double-blind, Randomised, Phase 3b MAXIMISE Trial. <i>Rheumatology</i> , 2022, 61, .	2.0	0
61	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. <i>Rheumatology</i> , 2022, 62, 98-107.	2.0	2
62	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	4.2	9
63	Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France. <i>Journal of Rheumatology</i> , 2022, 49, 1176-1178.	2.4	3
64	Defining and managing flares in axial spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2022, , .	3.8	7
65	Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: <scp>Threeâ€Year</scp> Results From a Phase <scp>Ib</scp> Randomized Controlled Trial and Its <scp>Openâ€Label</scp> Extension Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1959-1970.	7.4	34
66	SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry. <i>RMD Open</i> , 2022, 8, e002322.	4.2	11
67	Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force. <i>RMD Open</i> , 2022, 8, e002518.	4.2	20
68	Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>RMD Open</i> , 2022, 8, e002508.	4.2	13
69	Comparing the Patientâ€Reported Physical Function Outcome Measures in a Realâ€Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602.	3.0	12
70	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 293-303.	12.4	44
71	Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors. <i>Joint Bone Spine</i> , 2021, 88, 105071.	2.3	9
72	Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). <i>Rheumatology</i> , 2021, 60, 888-895.	2.0	30

#	ARTICLE	IF	PR CITATIONS
73	Gender differences in patient journey to diagnosis and disease outcomes: results from the European Map of Axial Spondyloarthritis (EMAS). <i>Clinical Rheumatology</i> , 2021, 40, 2753-2761.	2.4	44
74	Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. <i>RMD Open</i> , 2021, 7, e001539.	4.2	15
75	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 509.	2.6	100
76	What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021, 60, 5292-5299.	2.0	7
77	Critères d'évaluation à collecter pour optimiser la prise en charge de routine de la spondyloarthrite axiale: proposition fondée sur des preuves et une rencontre d'experts. <i>Revue Du Rhumatisme (Edition) Tj</i> 2021, 10, 784-791.	1.0	14
78	SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e481-e488.	10.7	35
79	Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1436-1444.	12.4	95
80	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	12.4	196
81	Les déterminants des troubles du sommeil dans le rhumatisme psoriasique : Étude observationnelle portant sur 696 patients de 14 pays. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 201-207.	0.0	0
82	Numérique et activités physiques en rhumatologie. <i>Revue Du Rhumatisme Monographies</i> , 2021, 88, 237-242.	0.0	0
83	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1419-1428.	12.4	28
84	Freins et croyances en rhumatologie dans la pratique de l'activité physique. <i>Revue Du Rhumatisme Monographies</i> , 2021, 88, 231-236.	0.0	0
85	Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, .	4.2	19
86	Outcome measures used in psoriatic arthritis registries and cohorts: A systematic literature review of 27 registries or 16,183 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 888-894.	3.9	18
87	Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. <i>Clinical Rheumatology</i> , 2021, , .	2.4	2
88	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	10.7	48
89	Young people's perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force. <i>RMD Open</i> , 2021, 7, e001517.	4.2	12
90	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	12.4	586

#	ARTICLE	IF	PR CITATIONS
91	Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 582-590.	12.4	157
92	Wearable activity trackers and artificial intelligence in the management of rheumatic diseases. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 928-935.	0.8	22
93	Influence of perceived barriers and facilitators for physical activity on physical activity levels in patients with rheumatoid arthritis or spondyloarthritis: a cross-sectional study of 150 patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, .	2.2	17
94	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	10.7	45
95	Machine learning approaches to improve disease management of patients with rheumatoid arthritis: review and future directions. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1311-1321.	3.7	25
96	Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 6-14.	2.4	5
97	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). <i>Rheumatology</i> , 2020, 59, 1495-1504.	2.0	25
98	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 854-864.	2.4	15
99	Criteria for inclusion in programs of functional restoration for chronic low back pain: Pragmatic Study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2020, 63, 189-194.	3.7	5
100	Spinal-pelvic orientation: potential effect on the diagnosis of spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 84-89.	2.0	4
101	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	3.0	49
102	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.9	7
103	Impact du rhumatisme psoriasique sur la qualité de vie. <i>Revue Du Rhumatisme Monographies</i> , 2020, 87, 288-294.	0.0	3
104	Wearable Activity Trackers in the Management of Rheumatic Diseases: Where Are We in 2020?. <i>Sensors</i> , 2020, 20, 4797.	3.1	28
105	Development and initial validation of a questionnaire to assess facilitators and barriers to physical activity for patients with rheumatoid arthritis, axial spondyloarthritis and/or psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 2085-2095.	2.7	29
106	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 778-786.	12.4	113
107	The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status. <i>Rheumatology</i> , 2020, 59, 3458-3467.	2.0	8
108	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	12.4	1,006

#	ARTICLE	IF	PR CITATIONS
109	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 709-718.	3.9	31
110	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	12.4	221
111	Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 701-708.	3.9	14
112	Effectiveness of a short functional restoration program for patients with chronic low back pain: A cohort study of 193 patients. <i>Joint Bone Spine</i> , 2020, 87, 640-646.	2.3	5
113	Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. <i>Rheumatology</i> , 2020, 59, 1818-1825.	2.0	49
114	Recommandations pour le traitement du rhumatisme psoriasique en 2020. <i>Revue Du Rhumatisme Monographies</i> , 2020, 87, 320-325.	0.0	0
115	Le savoir nécessaire aux patients atteints de polyarthrite rhumatoïde ou de spondyloarthrite. Résultats d'une enquête multicentrique française auprès de professionnels de santé et de patients. <i>Revue Du Rhumatisme (Edition Française)</i> , 2020, 87, 194-199.	0.0	2
116	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	12.4	85
117	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454.	2.3	18
118	How COVID-19 is changing rheumatology clinical practice. <i>Nature Reviews Rheumatology</i> , 2020, 17, 11-15.	27.8	32
119	Data to be collected for an optimal management of axial spondyloarthritis in daily practice: Proposal from evidence-based and consensual approaches. <i>Joint Bone Spine</i> , 2020, 87, 405-411.	2.3	18
120	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. <i>RMD Open</i> , 2020, 6, e001432.	4.2	31
121	Needs, Experiences, and Views of People With Rheumatic and Musculoskeletal Diseases on Self-Management Mobile Health Apps: Mixed Methods Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14351.	4.9	47
122	Essential knowledge for patients with rheumatoid arthritis or spondyloarthritis: Results of a multicentric survey in France among health professionals and patients. <i>Joint Bone Spine</i> , 2019, 86, 747-752.	2.3	22
123	Knowledge of and expectations about functional restoration programs for chronic low back pain: A mirror survey of 150 patients and 80 physicians in 2017. <i>Joint Bone Spine</i> , 2019, 86, 812-813.	2.3	0
124	Evaluation of the performances of "typical" imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study. <i>RMD Open</i> , 2019, 5, e000918.	4.2	18
125	Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. <i>RMD Open</i> , 2019, 5, e000914.	4.2	17
126	Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations. <i>RMD Open</i> , 2019, 5, e001004.	4.2	36

#	ARTICLE	IF	PR CITATIONS
127	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1028-1035.	2.4	82
128	Effet des traitements biologiques sur la fatigue dans le rhumatisme psoriasique: revue systématique de la littérature et méta-analyse. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 420-425.	0.0	0
129	Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. Journal of Rheumatology, 2019, 46, 1259-1267.	2.4	14
130	Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain. Arthritis Research and Therapy, 2019, 21, .	4.2	3
131	Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients. Rheumatology, 2019, 58, 1498-1499.	2.0	7
132	The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective – an Analysis of 2846 Patients Across 13 Countries. Current Rheumatology Reports, 2019, 21, .	4.4	92
133	Assessment of the adherence to disease-modifying drugs in patients with chronic inflammatory rheumatic diseases: Results of a survey of 1594 patients. Joint Bone Spine, 2019, 86, 610-614.	2.3	11
134	Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. Rheumatology, 2019, 58, 1649-1654.	2.0	29
135	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. Journal of Rheumatology, 2019, 46, 1021-1027.	2.4	124
136	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1014-1020.	2.4	87
137	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open, 2019, 5, e001014.	4.2	94
138	Recommandations pour l'évaluation et l'optimisation de l'adhésion aux traitements de fond médicamenteux des rhumatismes inflammatoires chroniques: un processus basé sur des revues de la littérature et un consensus d'experts. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 555-562.	0.0	1
139	Impact of comorbidities on fatigue in rheumatoid arthritis patients: Results from a nurse-led program for comorbidities management (COMEDRA). Joint Bone Spine, 2019, 86, 55-60.	2.3	30
140	Use of Wearable Activity Trackers to Improve Physical Activity Behavior in Patients With Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Analysis. Arthritis Care and Research, 2019, 71, 758-767.	3.0	95
141	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. Journal of Rheumatology, 2019, 46, 990-995.	2.4	53
142	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Annals of the Rheumatic Diseases, 2019, 78, 201-208.	12.4	70
143	Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine, 2019, 86, 135-150.	2.3	111
144	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. Arthritis Care and Research, 2019, 71, 1556-1565.	3.0	69

#	ARTICLE	IF	PR CITATIONS
145	Actualisation des Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 8-24.	0.0	25
146	Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. Joint Bone Spine, 2019, 86, 13-19.	2.3	44
147	Detection of Flares by Decrease in Physical Activity, Collected Using Wearable Activity Trackers in Rheumatoid Arthritis or Axial Spondyloarthritis: An Application of Machine Learning Analyses in Rheumatology. Arthritis Care and Research, 2019, 71, 1336-1343.	3.0	130
148	Mobile Health Apps for Self-Management of Rheumatic and Musculoskeletal Diseases: Systematic Literature Review. JMIR MHealth and UHealth, 2019, 7, e14730.	4.9	93
149	Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. Clinical Rheumatology, 2018, 37, 1503-1510.	2.4	15
150	2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. Joint Bone Spine, 2018, 85, 275-284.	2.3	83
151	Quality of life in psoriatic arthritis. Expert Review of Clinical Immunology, 2018, 14, 405-417.	3.7	171
152	Actualisation 2018 des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 10-17.	0.0	0
153	The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries. Rheumatology, 2018, 57, 300-308.	2.0	39
154	An e-health interactive self-assessment website (Sanoia®) in rheumatoid arthritis. A 12-month randomized controlled trial in 320 patients. Joint Bone Spine, 2018, 85, 709-714.	2.3	59
155	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 476-479.	12.4	57
156	Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program. RMD Open, 2018, 4, e000619.	4.2	12
157	Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis. Joint Bone Spine, 2018, 85, 405-410.	2.3	26
158	Développement et validation d'un questionnaire identifiant différentes stratégies comportementales chez les patients lombalgiques chroniques. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 381-387.	0.0	0
159	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. Arthritis Care and Research, 2018, 70, 369-378.	3.0	97
160	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	12.4	582
161	La rémission est associée à la CRP et au tabagisme dans la spondyloarthrite axiale douloureuse. La cohorte DESIR. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 178-182.	0.0	0
162	Facteurs associés à la connaissance générale et à celle des éléments de sécurité des patients sous biothérapie pour un rhumatisme inflammatoire: Étude de 677 patients. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 10-17.	0.0	0

#	ARTICLE	IF	PR CITATIONS
163	An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 124-127.	12.4	72
164	La place de la e-santé et les objets connectés dans le traitement de patients atteints de polyarthrite rhumatoïde. <i>Revue Du Rhumatisme Monographies</i> , 2018, 85, 66-70.	0.0	1
165	Perception des poussées de polyarthrite rhumatoïde telles que rapportées par les patients: sous-analyse de l'essai STRASS sur les stratégies de diminution progressive du traitement. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 353-358.	0.0	0
166	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.9	62
167	Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 533-540.	12.4	99
168	Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 258-263.	12.4	18
169	Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. <i>Journal of Rheumatology</i> , 2018, 45, 6-13.	2.4	100
170	Le délai diagnostique de la spondyloarthrite axiale: étude transversale sur 432 patients. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 183-187.	0.0	0
171	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018, 4, e000756.	4.2	22
172	The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. <i>Advances in Rheumatology</i> , 2018, 58, .	2.0	7
173	EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018, 4, e000780.	4.2	20
174	Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort. <i>RMD Open</i> , 2018, 4, e000657.	4.2	41
175	The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models. <i>Quality of Life Research</i> , 2018, 27, 2909-2921.	2.1	8
176	Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review. <i>RMD Open</i> , 2018, 4, e000684.	4.2	47
177	Fears and beliefs of people living with rheumatoid arthritis: a systematic literature review. <i>Advances in Rheumatology</i> , 2018, 58, .	2.0	37
178	Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study. <i>JMIR MHealth and UHealth</i> , 2018, 6, e1.	4.9	59
179	Use of nonsteroidal anti-inflammatory drugs in early axial spondyloarthritis in daily practice: Data from the DESIR cohort. <i>Joint Bone Spine</i> , 2017, 84, 79-82.	2.3	9
180	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.4	120

#	ARTICLE	IF	PR CITATIONS
181	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. <i>Rheumatology</i> , 2017, , kew390.	2.0	38
182	Development and validation of a questionnaire categorizing behavioral strategies in patients with chronic low back pain. <i>Joint Bone Spine</i> , 2017, 84, 725-731.	2.3	3
183	Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 203-207.	12.4	84
184	Collecte et prise en charge de certaines comorbidités et facteurs de risque associés dans le cadre des rhumatismes inflammatoires chroniques dans la pratique quotidienne en France. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 123-131.	0.0	0
185	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	12.4	238
186	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	12.4	3,466
187	Mucopolysaccharidoses seen in adults in rheumatology. <i>Joint Bone Spine</i> , 2017, 84, 663-670.	2.3	21
188	The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 855-861.	12.4	80
189	Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1036-1041.	12.4	33
190	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	2.0	76
191	Utilisation des anti-inflammatoires non-stéroïdiens dans la spondylarthrite axiale douloureuse en pratique quotidienne: données de la cohorte DESIR. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 516-519.	0.0	0
192	Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients. <i>Rheumatology and Therapy</i> , 2017, 4, 219-231.	2.2	55
193	Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial. <i>Joint Bone Spine</i> , 2017, 84, 577-581.	2.3	11
194	Patient-reported Flares in Ankylosing Spondylitis: A Cross-sectional Analysis of 234 Patients. <i>Journal of Rheumatology</i> , 2017, 44, 425-430.	2.4	18
195	Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-sectional Study of 977 Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1504-1509.	3.0	31
196	Mapping the Effect of Psoriatic Arthritis Using the International Classification of Functioning, Disability and Health. <i>Journal of Rheumatology</i> , 2017, 44, 193-200.	2.4	35
197	Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid Arthritis Study) randomised controlled trial. <i>RMD Open</i> , 2017, 3, e000474.	4.2	14
198	Flares assessed weekly in patients with rheumatoid arthritis or axial spondyloarthritis and relationship with physical activity measured using a connected activity tracker: a 3-month study. <i>RMD Open</i> , 2017, 3, e000434.	4.2	42

#	ARTICLE	IF	PR CITATIONS
199	Validating Rheumatoid Arthritis Remission Using the Patients'™ Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	2.4	16
200	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 1544-1550.	2.4	25
201	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. <i>Journal of Rheumatology</i> , 2017, 44, 1551-1559.	2.4	35
202	Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts. <i>Arthritis Research and Therapy</i> , 2017, 19, .	4.2	18
203	Diagnostic delay in axial spondyloarthritis: A cross-sectional study of 432 patients. <i>Joint Bone Spine</i> , 2017, 84, 467-471.	2.3	63
204	Remission is related to CRP and smoking in early axial spondyloarthritis. The DESIR cohort. <i>Joint Bone Spine</i> , 2017, 84, 473-476.	2.3	14
205	Factors associated with knowledge and safety skills of arthritis patients receiving biologics: A survey of 677 patients. <i>Joint Bone Spine</i> , 2017, 84, 163-168.	2.3	13
206	Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. <i>Joint Bone Spine</i> , 2016, 83, 501-509.	2.3	43
207	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	12.4	223
208	Translating patient reported outcome measures: methodological issues explored using cognitive interviewing with three rheumatoid arthritis measures in six European languages. <i>Rheumatology</i> , 2016, 55, 1009-1016.	2.0	15
209	The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles. <i>Journal of Rheumatology</i> , 2016, 43, 1300-1305.	2.4	45
210	Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 974-978.	2.4	15
211	Physical activity in patients with axial spondyloarthritis: a cross-sectional study of 203 patients. <i>Rheumatology International</i> , 2016, 36, 1711-1718.	2.7	40
212	Amélioration des résultats rapportés par les patients atteints de polyarthrite rhumatoïde traités par rituximab: Évaluation ouverte de 175 patients. <i>Revue Du Rhumatisme (Edition Française)</i> , 2016, 83, 457-460.	0.0	0
213	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	2.4	25
214	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750.	27.8	72
215	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , 2016, 18, .	4.2	221
216	Rheumatology training experience across Europe: analysis of core competences. <i>Arthritis Research and Therapy</i> , 2016, 18, .	4.2	20

#	ARTICLE	IF	PR CITATIONS
217	Prevalence of Renal Impairment in Patients With Rheumatoid Arthritis: Results From a Cross-sectional Multicenter Study. <i>Arthritis Care and Research</i> , 2016, 68, 638-644.	3.0	33
218	Patient-Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. <i>Arthritis Care and Research</i> , 2016, 68, 1767-1773.	3.0	99
219	Fatigue in psoriatic arthritis: A cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016, 83, 439-443.	2.3	56
220	Preliminary definitions of "flare" in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 991-996.	12.4	58
221	In rheumatoid arthritis, country of residence has an important influence on fatigue: results from the multinational COMORA study. <i>Rheumatology</i> , 2016, 55, 735-744.	2.0	26
222	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	12.4	103
223	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 499-510.	12.4	775
224	Fatigue in early axial spondyloarthritis. Results from the French DESIR cohort. <i>Joint Bone Spine</i> , 2016, 83, 427-431.	2.3	24
225	Patient global assessment in psoriatic arthritis: what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016, 83, 335-340.	2.3	40
226	In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 715-720.	12.4	45
227	Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1661-1666.	12.4	33
228	Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. <i>Journal of Rheumatology</i> , 2016, 43, 187-193.	2.4	52
229	Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000019.	4.2	108
230	Fatigue in Egyptian patients with rheumatic diseases: a qualitative study. <i>Health and Quality of Life Outcomes</i> , 2015, 13, .	3.0	19
231	Brief Report: Nonsteroidal Antiinflammatory Drug-Sparing Effect of Tumor Necrosis Factor Inhibitors in Early Axial Spondyloarthritis: Results From the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2015, 67, 2363-2368.	7.4	13
232	Impact of repeated measures of joint space width on the sample size calculation: An application to hip osteoarthritis. <i>Joint Bone Spine</i> , 2015, 82, 172-176.	2.3	5
233	Étude transversale des complications de survenue de 677 patients traités par biomédicament pour un rhumatisme inflammatoire. <i>Revue Du Rhumatisme (Edition Française)</i> , 2015, 82, 29-34.	0.0	0
234	Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis. <i>International Journal of Cardiology</i> , 2015, 183, 149-154.	2.3	17

#	ARTICLE	IF	PR CITATIONS
235	A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study. <i>Rheumatology</i> , 2015, 54, 1161-1169.	2.0	11
236	Differences and similarities in rheumatology specialty training programmes across European countries. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1183-1187.	12.4	19
237	Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT. <i>Journal of Rheumatology</i> , 2015, 42, 1943-1946.	2.4	9
238	Enhanced Patient Involvement and the Need to Revise the Core Set " Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	2.4	36
239	Outcome Domains and Measures in Total Joint Replacement Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative. <i>Journal of Rheumatology</i> , 2015, 42, 2496-2502.	2.4	30
240	EULAR recommendations for patient education for people with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 954-962.	12.4	331
241	Intra-articular injections in thumb osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. <i>Joint Bone Spine</i> , 2015, 82, 315-319.	2.3	46
242	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1725-1733.	12.4	152
243	Version patient des recommandations de prise en charge de la polyarthrite rhumatoïde: une collaboration entre la Société française de rhumatologie et des associations de patients atteints de polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, 373-377.	0.0	1
244	Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2361-2368.	2.4	3
245	Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients. <i>Joint Bone Spine</i> , 2015, 82, 451-454.	2.3	9
246	Evaluation of Serum Interleukin-6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 905-912.	3.0	58
247	Repeated Anticitrullinated Protein Antibody and Rheumatoid Factor Assessment Is Not Necessary in Early Arthritis: Results from the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 41-46.	2.4	18
248	Updating the OMERACT Filter: Discrimination and Feasibility. <i>Journal of Rheumatology</i> , 2014, 41, 1005-1010.	2.4	22
249	Reporting of patient-perceived impact of rheumatoid arthritis and axial spondyloarthritis over 10 years: a systematic literature review. <i>Rheumatology</i> , 2014, 53, 1274-1281.	2.0	24
250	How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0. <i>Journal of Rheumatology</i> , 2014, 41, 1025-1030.	2.4	89
251	Clinical measurement of disease activity in rheumatoid arthritis: why, how and utility of patient self-assessment. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 327-339.	0.4	0
252	Assessing structural changes in axial spondyloarthritis using a low-dose biplanar imaging system. <i>Rheumatology</i> , 2014, 53, 1669-1675.	2.0	12

#	ARTICLE	IF	PR CITATIONS
253	Cross-sectional study of self-care safety skills in 677 patients on biodrugs for inflammatory joint disease. <i>Joint Bone Spine</i> , 2014, 81, 502-507.	2.3	13
254	Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of "Truth" Content, Face, and Construct Validity. <i>Journal of Rheumatology</i> , 2014, 41, 1000-1004.	2.4	35
255	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. <i>Journal of Rheumatology</i> , 2014, 41, 1011-1015.	2.4	55
256	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. <i>Journal of Rheumatology</i> , 2014, 41, 994-999.	2.4	21
257	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 745-753.	3.7	713
258	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 516-528.	12.4	289
259	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 529-535.	12.4	477
260	Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 287-297.	2.3	126
261	Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Française)</i> , 2014, 81, 303-312.	0.0	12
262	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 510-515.	12.4	127
263	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	12.4	379
264	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	12.4	1,744
265	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, .	4.4	39
266	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	12.4	416
267	Reliability of joint count assessment in rheumatoid arthritis: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 721-729.	3.9	61
268	Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers. <i>Journal of Rheumatology</i> , 2014, 41, 1016-1024.	2.4	14
269	When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. <i>Annals of the New York Academy of Sciences</i> , 2014, 1318, 32-40.	4.1	25
270	The learning curve of nurses for the assessment of swollen and tender joints in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 154-159.	2.3	17

#	ARTICLE	IF	PR CITATIONS
271	Patient perspective in outcome measures developed by OMERACT. Indian Journal of Rheumatology, 2013, 8, S17-S22.	0.3	9
272	Tolérance des biothérapies: élaboration et validation d'un questionnaire évaluant les compétences d'auto-gestion et de sécurité du patient: le questionnaire BioSecure. Une initiative de la Société française de rhumatologie, section éducation thérapeutique. Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.0	3
273	Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis. Joint Bone Spine, 2013, 80, 29-33.	2.3	251
274	Safety of biologics: Elaboration and validation of a questionnaire assessing patients' self-care safety skills: The BioSecure questionnaire. An initiative of the French Rheumatology Society Therapeutic Education section. Joint Bone Spine, 2013, 80, 471-476.	2.3	37
275	Autonomous online health assessment questionnaire registry in daily clinical practice. Rheumatology, 2013, 52, 883-887.	2.0	15
276	Pattern of demyelination occurring during anti-TNF- α therapy: a French national survey. Rheumatology, 2013, 52, 868-874.	2.0	129
277	Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. Annals of the Rheumatic Diseases, 2012, 71, 1942-1949.	12.4	66
278	Assessment of work instability in spondyloarthritis: a cross-sectional study using the ankylosing spondylitis work instability scale. Rheumatology, 2012, 51, 333-337.	2.0	21
279	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 2012, 71, 319-326.	12.4	239
280	Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Research and Therapy, 2012, 14, .	4.2	69
281	Abatacept therapy and safety management. Joint Bone Spine, 2012, 79, 3-84.	2.3	51
282	The Impact of Coping Strategies on Mental and Physical Well-Being in Patients with Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism, 2012, 41, 545-555.	3.9	60
283	Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care and Research, 2012, 64, 206-214.	3.0	158
284	Clinical outcomes in psoriatic arthritis: A systematic literature review. Arthritis Care and Research, 2012, 64, 397-406.	3.0	54
285	TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine, 2011, 78, 15-185.	2.3	66
286	On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al. Arthritis and Rheumatism, 2011, 63, 3182-3185.	6.0	1
287	OARSI/OMERACT Initiative to Define States of Severity and Indication for Joint Replacement in Hip and Knee Osteoarthritis. An OMERACT 10 Special Interest Group. Journal of Rheumatology, 2011, 38, 1765-1769.	2.4	73
288	Tocilizumab: Therapy and safety management. Joint Bone Spine, 2010, 77, S3-S100.	2.3	54

#	ARTICLE	IF	PR CITATIONS
289	Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: Meta-analysis of randomized controlled trials. <i>Arthritis Care and Research</i> , 2010, 62, 984-992.	3.0	179
290	Relative Clinical Influence of Clinical, Laboratory, and Radiological Investigations in Early Arthritis on the Diagnosis of Rheumatoid Arthritis. Data from the French Early Arthritis Cohort ESPOIR. <i>Journal of Rheumatology</i> , 2010, 37, 2486-2492.	2.4	23
291	Patient-Reported Outcomes in Rheumatoid Arthritis: Why are They Important and How Should They Be Assessed?. <i>Turkish Journal of Rheumatology</i> , 2010, 25, 99-104.	0.1	13
292	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	12.4	1,480
293	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1004-1009.	12.4	187
294	Reporting of Adherence to Medication in Recent Randomized Controlled Trials of 6 Chronic Diseases: A Systematic Literature Review. <i>American Journal of the Medical Sciences</i> , 2007, 334, 248-254.	0.8	76
295	Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 0, , annrhumdis-2017-212612.	12.4	24
296	Prediction of Work Impact in Axial Spondylarthritis by the Work Instability Scale: A Prospective Cohort Study Of 101 Patients. <i>Journal of Rheumatology</i> , 0, , jrheum.191397.	2.4	0
297	Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. <i>Journal of Rheumatology</i> , 0, , jrheum.211288.	2.4	7
298	EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 0, , ard-2023-224148.	12.4	76
299	The Effectiveness of Digital Apps Providing Personalized Exercise Videos: Systematic Review With Meta-Analysis. <i>Journal of Medical Internet Research</i> , 0, 25, e45207.	4.9	15
300	Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial. <i>JMIR Research Protocols</i> , 0, 12, e52872.	1.3	8
301	Psychometric Properties of Patient Global Assessment in Psoriatic Arthritis: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 0, , jrheum.2023-0722.	2.4	1